Phathom Pharmaceuticals, Inc. - 8-K Filing
Phathom Pharmaceuticals held its 2026 Annual Meeting of Stockholders on May 19, 2026. Shareholders elected three Class I directors (Steven Basta, Theodore R. Schroeder, Mark Stenhouse) for a three-year term and ratified Ernst & Young LLP as the independent registered public accounting firm with overwhelming support. They also approved executive compensation on an advisory basis. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $PHAT